Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Top Cited Papers
- 29 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (1), 38-43
- https://doi.org/10.1093/infdis/jiaa228
Abstract
Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.Keywords
Funding Information
- National Natural Science Foundation of China (81970517)
- Thousands Outstanding Talents Plan (ZYQR201912179)
- Zhengzhou University Medical School (2020ZQLMS)
- Henan Higher Education Institutions of China (20B320028)
This publication has 15 references indexed in Scilit:
- Positive RT-PCR Test Results in Patients Recovered From COVID-19JAMA, 2020
- Presumed Asymptomatic Carrier Transmission of COVID-19JAMA, 2020
- First Case of 2019 Novel Coronavirus in the United StatesThe New England Journal of Medicine, 2020
- What to do next to control the 2019-nCoV epidemic?The Lancet, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnosticNanomedicine: Nanotechnology, Biology and Medicine, 2019
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patientsClinical Microbiology & Infection, 2004
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003